



شبكة المعلومات الجامعية

بسم الله الرحمن الرحيم



شبكة المعلومات الجامعية  
@ ASUNET



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأفلام قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of  
15-25- c and relative humidity 20-40%

# بعض الوثائق الأصلية تالفة

# بالرسالة صفحات لم ترد بالاصل



# ANTICARDIOLIPIN ANTIBODIES AND CARDIAC INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

## Thesis

*Submitted for Partial fulfillment of M.D. Degree*

*In*

**"Rheumatology and Rehabilitation"**

*By*

٣٣.٠٥

**Abeer ahmed ismael soliman**

(M.B.B.Ch., M.Sc.)

## Supervisors

Prof. Dr.

**MOHAMED ZAKRIA ERAKY**

Professor & Head of Rheumatology &  
Rehabilitation Department  
Faculty of Medicine  
Benha University

Prof. Dr

**MOUNIR SERAG EL-DIN**

Professor of Rheumatology & Rehabilitation  
Faculty of Medicine  
Benha University

Prof. Dr

**HAMZA M. KABIL**

Assit. Professor of Cardiology  
Faculty of Medicine  
Benha University

Dr

**EMAN M. MOUNIR**

lecturer of Rheumatology & Rehabilitation  
Faculty of Medicine  
Benha University

**FACULTY OF MEDICINE  
BENHA UNIVERSITY**

**2005**



A large, stylized handwritten signature in black ink, located at the bottom left of the page.

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ سُبْحَانَ اللَّهِ عَمَّا يُشْرِكُونَ  
إِنِّي أَنذِرُكُمْ يَوْمَ تَأْتِي السُّحُبُ بِمَطَرٍ مِّنَ الْغَشَمِ

صدق الله العظيم

(البقرة ٣٢)

First , and for most thanks to **ALLAH**,  
the most merciful, gracious and  
compassionate, to **ALLAH**  
everything in life is resumed.



# Acknowledgment

I would like to express my sincere gratitude and deep appreciation to Prof. Dr. **MOHAMED ZAKRIA ERAKY** Professor & Head of Rheumatology & Rehabilitation Department Faculty of Medicine, Benha University , for his continuous scientific guidance, enriching me with his vast experience, unlimited help, full provision of all facilities, the precious time and effort.

I am delighted to express my deep gratitude and sincere thanks to, Prof. Dr. **MOUNIR SERAG EL-DIN** Professor of Rheumatology & Rehabilitation Faculty of Medicine Benha University , for his great help and experienced guidance throughout the period of the work.

I am greatly indebted to Prof. Dr. **HAMZA M. KABIL** Assit. Professor of Cardiology Faculty of Medicine Benha University for his scientific guidance, helpful cooperation, effective advice and in exhaustible patience throughout the entire work.

My appreciation and deep thanks are extended to Dr. **EMAN M. MOUNIR** Lecturer of Rheumatology & Rehabilitation Faculty of Medicine, Benha University for her instructive supervision, experienced guidance and meticulous revision, I feel to her much respect and I give her my warmest thanks.

Lastly, Thanks to all who offered to me any help which made this work an existing reality

# CONTENTS

	Page
INTRODUCTION.....	1
AIM OF THE WORK.....	3
REVIEW OF LITERATURE	
❧ Systemic lupus erythematosus .....	4
• Incidence and prevalence .....	4
• Etiology.....	4
• Pathogenesis of Systemic lupus erythematosus.....	7
• Pathology of Systemic lupus erythematosus.....	14
• Clinical Presentation of SLE .....	18
• Investigations.....	27
• Prognosis of systemic lupus erythematosus.....	35
• Management of systemic lupus erythematosus .....	37
❧ Antiphospholipid antibody syndrome.....	44
❧ Antiphospholipid antibodies.....	46
❧ Cardiac abnormalities in SLE and association with raised aCL antibodies .....	63
❧ Anticardiolipin antibodies and disease activity in SLE.....	71
❧ Echocardiographic abnormalities in systemic lupus erythematosus.....	73
Patients AND METHODS.....	79
RESULTS .....	99
DISCUSSION.....	136
SUMMARY AND CONCLUSION.....	151
References .....	156
Arabic summary	

## LIST OF TABLE

Ταβλε No.	Παγε
<b>Table (1):</b> Clinical data of SLE patients.....	102
<b>Table (2):</b> Duration of illness and SLEDAI in SLE patients.....	102
<b>Table (3):</b> Treatment received by SLE patients.....	103
<b>Table (4):</b> Prevalence of ANA and anti DNA tests among SLE patients.....	103
<b>Table (5):</b> Laboratory data of SLE patients.....	104
<b>Table (6):</b> Echo changes of SLE patients.....	104
<b>Table (7):</b> Classification of SLE patients according to disease activity grading.....	105
<b>Table (8):</b> Comparison between SLE patients and the control group as regard age (in years) .....	107
<b>Table (9):</b> Comparison between SLE patients and the control group as regard sex..	107
<b>Table (10):</b> Comparison between SLE patients and control group as regard ESR....	108
<b>Table (11):</b> Comparison between SLE patients and control group as regard Ejection Fraction (EF).....	109
<b>Table (12):</b> Comparison between SLE patients and control group as regard anti- cardiolipin antibodies .....	110
<b>Table (13):</b> Prevalence of anti-cardiolipin antibodies among SLE patients.....	113
<b>Table (14):</b> Comparison between clinical data and anti-cardiolipin antibodies in SLE patients.....	114
<b>Table (15):</b> Comparison between laboratory data and anti-cardiolipin antibodies among SLE patients.....	116
<b>Table (16):</b> Relationship between anti-cardiolipin and echo findings.....	118
<b>Table (17):</b> Relationship between anti-cardiolipin and disease activity in SLE patients .....	120
<b>Table (18):</b> Correlation between anti-cardiolipin and echo findings.....	121
<b>Table (19):</b> Prevalence of echo changes among SLE patients.....	124
<b>Table (20):</b> Comparison between clinical data and Echo changes in SLE patients.....	125



<b>Table (21):</b> Comparison between laboratory data and Echo changes among SLE patients .....	127
<b>Table (22):</b> Relationship between echo changes and disease activity in patient group.....	129
<b>Table (23):</b> Relationship between echo changes and disease activity .....	130
<b>Table (24)</b> Correlation between anti-cardiolipin antibodies and Ejection Fraction1	132
<b>Table (25):</b> Comparison between Ejection Fraction (EF) and anti-cardiolipin antibodies among SLE patients .....	133
<b>Table (26):</b> Correlation between Ejection Fraction and disease activity in SLE patients .....	133
<b>Table (27):</b> Correlation between age, sex, and duration of illness with aCL IgG, echo changes and Ejection Fraction.....	134
<b>Table (28):</b> Relationship between echo changes and anti-cardiolipin in SLE patients .....	135

# LIST OF FIGURES

Φγ. No.		Παγε
<b>Review of Literature</b>		
<b>Fig. (I):</b>	Possible mechanisms of Autoantibody Production.....	8
<b>Fig. (II):</b>	Activation of B cells to produce antibodies in SLE patients .....	11
<b>Fig. (III):</b>	Several proposed mechanisms for the evolution of a clinical event in the APS syndrome.....	45
<b>Fig. (IV):</b>	A normal mitral valve "gross picture" .....	66
<b>Fig. (V):</b>	Mitral valve with vegetations of Libman- Sacks endocarditis in patients with SLE .....	66
<b>SUBJECTS AND METHODS</b>		
<b>Fig. (VI):</b>	The Anticardiolipin ELISA.....	90
<b>Fig. (VII):</b>	Normal Echocardiographic study.....	96
<b>Fig. (VIII):</b>	Trivial MR in SLE patient .....	96
<b>Fig. (IX):</b>	Mild MR in SLE patient .....	96
<b>RESULTS</b>		
<b>Fig. (1):</b>	Classification of SLE patients according to disease activity grading.....	105
<b>Fig. (2):</b>	Comparison between SLE patients and control group as regard ESR.....	108
<b>Fig. (3):</b>	Comparison between SLE patients and control group as regard Ejection Fraction (EF).....	109
<b>Fig. (4):</b>	Comparison between SLE patients and control group as regard anti-cardiolipin antibodies .....	110
<b>Fig. (5):</b>	Prevalence of anti-cardiolipin antibodies among SLE patients.....	113
<b>Fig. (6):</b>	Comparison between clinical data and anti-cardiolipin antibodies in SLE patients .....	115
<b>Fig. (7):</b>	Comparison between laboratory data and anticardiolipin antibodies among SLE patients.....	117
<b>Fig. (8):</b>	Relationship between anti-cardiolipin and Mitral regurg .....	119
<b>Fig. (9):</b>	Relationship between anti-cardiolipin and disease activity in SLE patients .....	120
<b>Fig. (10):</b>	Prevalence of echo changes among SLE patients.....	124
<b>Fig. (11):</b>	Comparison between clinical data and echo changes in SLE.....	126
<b>Fig. (12):</b>	Comparison between laboratory data and echo changes among SLE patients .....	128
<b>Fig. (13):</b>	Relationship between echo changes and disease activity in patient group.	129
<b>Fig. (14):</b>	Relationship between Mitral regurg and disease activity .....	131
<b>Fig. (15):</b>	Comparison between Ejection Fraction (EF) and anti-cardiolipin antibodies among SLE patients .....	133
<b>Fig. (16):</b>	Relationship between echo changes and anti-cardiolipin in SLE patients..	135

## Abbreviations

Ab	:	Antibodies
aCL Ab	:	Anticardiolipin antibodies
ACR criteria	:	American College of Rheumatology criteria
ANA	:	Antinuclear antibodies
anti-ds DNA	:	Anti-double stranded DNA
aPL	:	Antiphospholipid antibodies
APS	:	Antiphospholipid syndrome
APTT	:	Activated partial thromboplastin time
B.M.Z.	:	Basement membrane zone
B <sub>2</sub> glycoprotein I	:	Beta <sub>2</sub> glycoprotein I
B <sub>2</sub> -GPI	:	Beta <sub>2</sub> glycoprotein I
C <sub>1,2</sub>	:	Complement 1,2
CL	:	Cardiolipin
CNS	:	Central nervous system
COX-1	:	Cyclooxygenase 1
COX-2	:	Cyclooxygenase 2
CRP	:	C- reactive protein
CVA	:	Cerebrovascular accidents
Ds	:	Double stranded
DT	:	Deceleration
ECG	:	Electrocardiography
Echo	:	Echocardiography
EF	:	Ejection fraction
ELISA	:	Enzyme linked immunosorbent assay
ESR	:	Erythrocyte sedimentation rate
FANA	:	Elorescent antinuclear antibody
GIT	:	Gastrointestinal tract
H <sub>2</sub> O <sub>2</sub>	:	Hydrogen peroxide
Hb	:	Hemoglobin
HELLP	:	Hemolysis, elevated liver enzymes, low platelets
HIV	:	Human immunodeficiency virus
HLA	:	Human leukocyte antigen
HRP	:	Horse radish peroxidase
Ig A	:	Immunoglobulin A
Ig G	:	Immunoglobulin G
Ig M	:	Immunoglobulin M
Ig	:	Immunoglobulin
INR	:	International normalized ratio
IVRT	:	Isovolumic relaxation time
LA	:	Lupus anticoagulants
LDH	:	Lactate dehydrogenase



LE	:	Lupus erythematosus
LV	:	Left ventricular
MHC	:	Major histocompatibility complex
MRI	:	Magnetic resonance imaging
NAA	:	Neutrophil aggregation activity
NP-SLE	:	Neuropsychiatric- SLE
NSAIDs	:	Non-steroidal anti inflammatory drugs
O.D.	:	Optical density
PA	:	Phosphatidic acid
PAPS	:	Primary antiphospholipid syndrome
PASP	:	Pulmonary artery systolic pressure
PC	:	Phosphatidylcholine
PE	:	Phosphatidylethanolamine
PG	:	Phosphatidylglycerol
PH	:	Pulmonary hypertension
PI	:	Phosphatidylinositol
PS	:	Phosphatidylserine
PT	:	Prothrombin time
PTT	:	Partial thromboplastin time
RA	:	Rheumatoid arthritis
RBCs	:	Red blood cells
Regurg	:	Regurgitation
RV	:	Right ventricular
sAPS	:	Secondary antiphospholipid syndrome
SD	:	Standard deviation
SGOT	:	Serum glutamate oxalacetate transferase
sIL-2	:	Soluble interleukin -2
SLE	:	Systemic lupus erythematosus
SLEDAI	:	Systemic lupus erythematosus disease activity index
sn RNPs	:	Small nuclear ribonucleoproteins
T.B.	:	Tuberculosis
TLC	:	Total leucocytic count
TMB	:	Tetramethylbenzidine
U1-RNP	:	U1 ribonucleoprotein
UV light	:	Ultra violet light
WBCs	:	White blood cells
+ve	:	Positive